Gsk Share Discussion Threads

[ianood] 02/3/2021 20:13

It still needs a CEO, internal or external appointee!

[roybel] 02/3/2021 20:09

Selling off the only department she's qualified / experienced enough to run !

[ianood] 02/3/2021 19:41

TM - and Hal Barron gets to run the R&D operation?

[watfordhornet] 02/3/2021 19:38

It's ridiculous.Why is she not giving it to charity? She cannot honestly think she deserves these awards

[tradermichael] 02/3/2021 19:29

GSK pays her to sit on several other boards to pass the time till she gets a sideways promotion to CEO (back) at the new Consumer Healthcare company.

Historically, for the record:

"When she takes over GlaxoSmithKline from Sir Andrew Witty on 1 April 2017, Walmsley will be running the biggest of those seven companies, with GSK ranking fourth in FTSE 100 with a market value of £80bn.

Investors gave a lukewarm response to the appointment of the 47-year-old, thought to be one of four internal candidates for the top job and someone with a marketing and consumer products – rather than scientific – background. Shares dropped 0.4% after the announcement.

Walmsley joined GSK in 2010 after 17 years at L’Oréal. She leads GSK’s consumer healthcare business, which was established in 2015 after a deal with Novartis, in which Walmsley was instrumental."

[roybel] 02/3/2021 17:21

Wonder if she has another job and this is part time !

[geckotheglorious] 02/3/2021 16:46

More trough snuffling by Emma Walmsley.

"Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American Depository Shares"

A deferred bonus??? For what? massive under performance?

This CEO is overpaid,and needs to go - the sooner the better.

[montyhedge] 02/3/2021 16:25

Have we broken away from the Astra trading in tandem with GSK, we are up they are down.

[montyhedge] 02/3/2021 14:32

Astra going down further, unfortunately GSK acts in tandem.Astra going nowhere until the bid concludes second half of the year.

[tradermichael] 02/3/2021 10:17

What he says is quite impressive, but it takes some effort to wade through it (he makes a better job of it than Emma could have done):

[spyder] 02/3/2021 09:11

To be fair, this is a transcript of an interview and that never comes across well in print form.

[spyder] 02/3/2021 08:30

Hal Barron comments from yesterday’s Cowen 41st Annual Health Care Conference March 1, 2021.
- “But just in 2020, last year alone, we had 9 approvals, actually, and 4 new molecular entities approved in a given year, which is pretty impressive for any company and certainly in my career.”
- “the governance model that we put in place, a very clear accountable decision-making framework that I think will add a lot of rigor to how we make decisions and who makes them. And ultimately, that will, I think, be helpful for ensuring that we're allocating capital appropriately to optimally invest in those projects that are most likely to help patients and benefit the company and deprioritizing those that weren't.”
- “I'm very excited about is our research strategy, which we put in place, focusing on human genetics, functional genomics and machine learning, the real -- a triad of these, what I think will ultimately be very disruptive technologies, has gone exceedingly well. I think we now have the largest genetic databases with 23andME and UK Biobank, FinnGen open targets.”

[montyhedge] 02/3/2021 08:05

Big support at 1200p, let's hope it holds. Otherwise 1150p.

[rikky72] 02/3/2021 07:32

Would have been vastly more impressive if they'd done that a few months ago! ;)

[spyder] 01/3/2021 17:18

Just in case you did not see this - ‘Citigroup cuts price target to 1317p from 1580p’

[spyder] 01/3/2021 16:51

Sorry - wrong thread for AML post!

[eurofox] 01/3/2021 16:08

VIR moving up +5%

[montyhedge] 01/3/2021 15:08

Ess
My target for Astra is 6250p and seeing GSK move in tandem I see possible 1125p, just on capitulation in the pharma sector, I like both shares, just my view.

[essentialinvestor] 01/3/2021 14:43

I don't see AZN below £66, barring something unforseen.

[montyhedge] 01/3/2021 14:41

Pharma sector needs capitulation before its goes better, to me Astra at 6200p and GSK
at 1125p, painful I know.

[essentialinvestor] 01/3/2021 14:02

Yes, significant de-rating in pharma sector earnings multiples over the
last 12 months - in general terms.

By pharma I'm referring to the largest listed companies, rather than biotech,
appreciate there is some overlapping.

[spyder] 01/3/2021 13:59

Edited - posted by mistake!

[montyhedge] 01/3/2021 13:44

May just go to 1125p pharmas so out of favour.

[tradermichael] 01/3/2021 12:05

More good news (from Friday):

GlaxoSmithKline PLC on Friday said the European regulator has adopted a positive opinion recommending dostarlimab, one of the final steps in the marketing authorisation procedure.

Dostarlimab is an anti-programmed-death-1 monoclonal antibody, which was recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency for use as monotherapy in women with mismatch repair deficient endometrial cancer, who have progressed on or following prior treatment with a platinum containing regimen.

The Brentford, England-headquartered pharmaceutical company said the application is based on data from the Garnet study.

Meanwhile, dostarlimab is also under review with the US Food & Drug Administration for the treatment of women with recurrent or advanced endometrial cancer. Dostarlimab is not currently approved for use anywhere in the world.

"This positive opinion brings us one step closer to providing dostarlimab as a new treatment option to women with endometrial cancer in Europe with the hope of improving outcomes. If approved by the European Commission, dostarlimab would be the first anti-PD-1 therapy approved for endometrial cancer in Europe," said Axel Hoos, senior vice president & head of Oncology Research & Development at GSK.